GBI Research, a business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar', which provides insights into bone metabolic disease therapeutics until 2018.